Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Smith & Nephew is a UK-based global medical device manufacturer with $5.8B in revenue, specializing in orthopedic reconstruction (hip/knee implants), sports medicine & ENT (arthroscopy, joint repair), and advanced wound management. The company competes in mature, innovation-driven markets against larger rivals like Stryker and Zimmer Biomet, with differentiation through robotics platforms (CORI surgical system) and advanced wound care technologies. Geographic diversification spans established markets (US ~45% of revenue, Europe ~30%) and emerging markets (Asia Pacific, Latin America ~25%).
Smith & Nephew operates a razor-and-blade model in orthopedics and wound care, selling capital equipment (surgical robots, wound therapy units) at modest margins while generating high-margin recurring revenue from disposable implants, instruments, and consumables. Pricing power derives from surgeon preference, clinical outcomes data, and switching costs once hospitals adopt specific systems. The company invests 5-6% of revenue in R&D to maintain technological differentiation, particularly in robotics-assisted surgery and biologics. Direct sales force relationships with orthopedic surgeons and hospital procurement committees create sticky customer relationships, though group purchasing organizations (GPOs) exert pricing pressure in the US market.
Elective surgery volumes in orthopedics (hip/knee replacements), which correlate with hospital capacity, patient confidence, and aging demographics
Market share gains or losses in robotics-assisted surgery platforms (CORI system adoption rates vs. Stryker's Mako)
Geographic revenue mix shifts, particularly emerging market growth rates (China, India) vs. mature market pricing pressure
Product pipeline milestones and FDA/CE Mark approvals for next-generation implants and wound care technologies
Currency headwinds or tailwinds given UK listing and global revenue base (USD strength typically negative)
Reimbursement pressure from government payers globally (CMS in US, NHS in UK) driving shift to value-based care and bundled payments, compressing device pricing power
Regulatory intensification post-medical device scandals (metal-on-metal hips, mesh implants), increasing approval timelines and post-market surveillance costs
Technological disruption from outpatient surgery centers and minimally invasive techniques reducing hospital procedure volumes and device utilization
Market share erosion to larger competitors with superior robotics platforms (Stryker Mako has 10x installed base vs. CORI) and broader product portfolios enabling bundled contracting
Commoditization of mature orthopedic implants as patents expire, with low-cost manufacturers in emerging markets capturing share in price-sensitive segments
Consolidation among hospital systems and GPOs increasing buyer power and intensifying pricing pressure on device manufacturers
Currency translation risk given UK domicile and global revenue base (USD strength reduces reported revenue/earnings for non-US sales)
Pension obligations in UK and US legacy plans, though current funding status appears adequate with 3.0x current ratio providing liquidity buffer
Litigation reserves for legacy product liability claims (metal-on-metal hip implants), though most major settlements concluded
moderate - Elective orthopedic procedures (60-70% of joint replacements) are deferrable during economic uncertainty when patients delay surgery due to out-of-pocket costs, employment concerns, or reduced insurance coverage. However, aging demographics (65+ population growth) provide structural tailwind independent of GDP. Wound care has lower cyclicality as it addresses acute trauma and chronic conditions. Emerging market exposure adds cyclical sensitivity to local GDP growth and healthcare infrastructure spending.
Rising rates have modest negative impact through two channels: (1) higher financing costs for hospital capital equipment purchases, potentially slowing adoption of robotic systems and wound therapy units, and (2) valuation multiple compression for med-tech stocks as discount rates rise. However, the company's moderate debt load (0.62x D/E) limits direct interest expense sensitivity. Rate increases that signal economic strength may support elective procedure volumes, partially offsetting valuation pressure.
Minimal direct credit exposure. Customer base is hospitals and healthcare systems with stable payment profiles, though reimbursement pressure from government payers (Medicare, NHS) and private insurers affects end-market pricing. Hospital financial stress during credit tightening can delay capital equipment purchases and pressure implant pricing through GPO negotiations.
value - The stock trades at 2.5x sales and 12.4x EV/EBITDA, below med-tech peers, attracting value investors betting on operational turnaround and margin expansion. Recent 57% net income growth signals improving profitability, though from depressed base. The 4.3% FCF yield appeals to investors seeking cash generation with modest growth (5% revenue growth). Limited dividend yield suggests focus on reinvestment rather than income. Institutional holders likely include healthcare-focused funds and UK equity managers given London listing.
moderate - Medical device stocks exhibit lower volatility than biotech (no binary drug approvals) but higher than large-cap pharma. Beta likely 0.8-1.0 range. Stock moves on quarterly earnings surprises, procedure volume data, and competitive dynamics in robotics. Currency volatility adds noise to reported results. Recent 18% one-year return with -6% six-month pullback reflects sector rotation and profit-taking after strong run.
